CPRX Q4 2025 Earnings Call Summary

Catalyst Pharmaceuticals (CPRX) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenues: $589 million for FY 2025, a 19.8% increase from $491.7 million in FY 2024, exceeding guidance of $565 million to $585 million.
Net Product Revenue: $588.8 million, up 20.3% year-over-year.
Q4 2025 Revenues: $152.6 million, a 7.6% increase from Q4 2024.
Net Income: GAAP net income of $214.3 million ($1.68 per diluted share), a 30.8% increase from $163.9 million in 2024.
Non-GAAP Net Income: $346.2 million ($2.72 per diluted share).
Cash and Cash Equivalents: $709.2 million at year-end, up from $517.6 million in 2024.

2. Strategic Updates and Business Highlights

FIRDAPSE: Revenue of $358.4 million in 2025, a 17% increase. The company is focusing on expanding its market share in idiopathic and cancer-associated LEMS, with significant growth opportunities identified.
AGAMREE: Achieved $117.1 million in revenue, a 154.3% increase year-over-year. The company is deepening its penetration in treatment centers and conducting ongoing studies to enhance its market position.
FYCOMPA: Generated $113.3 million in revenue despite losing exclusivity, with expectations of $40 million to $45 million in 2026 due to generic competition.
Business Development: Over 100 assessments conducted in 2025, with a focus on identifying differentiated rare disease products for potential acquisition.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Total revenue expected between $615 million and $645 million.
- FIRDAPSE: Projected revenue of $435 million to $450 million (21.4% to 25.6% growth).
- AGAMREE: Expected revenue of $140 million to $150 million (19.6% to 28.1% growth).
- FYCOMPA: Forecasted revenue of $40 million to $45 million.
The company anticipates continued growth driven by patient identification initiatives and market penetration strategies.

4. Bad News, Challenges, or Points of Concern

Generic Competition: FYCOMPA faces revenue erosion due to generic competition, impacting future sales.
Ongoing Litigation: One lawsuit remains against Hetero USA regarding FIRDAPSE, with a trial set for March 2026, which could affect market dynamics.
IRA Impact: The Inflation Reduction Act (IRA) is expected to increase gross-to-net deductions, impacting net product revenue from Medicare Part D.
Market Penetration: While there is optimism about growth, the company must navigate the complexities of patient identification and conversion, particularly in the cancer-associated LEMS market.

5. Notable Q&A Insights

FIRDAPSE Growth Drivers: Management highlighted a significant pool of patients in the diagnostic journey, with over 600 leads identified, and a 21% year-over-year increase in VGCC testing, which is crucial for patient conversion.
AGAMREE Adoption: The median age of new enrollees has dropped, indicating a shift towards younger patients, which is expected to enhance long-term adherence and treatment outcomes.
Reimbursement Landscape: AGAMREE's reimbursement approval rates are above 85%, with some pushback primarily due to step edits, but the company is confident in bridging patients to treatment during approval processes.
Business Development Outlook: Management remains optimistic about potential acquisitions, emphasizing a diligent approach to identifying products that align with their strategic goals.

Overall, Catalyst Pharmaceuticals demonstrated strong financial performance in 2025, with positive growth trajectories for its key products, while also facing challenges related to competition and ongoing litigation. The company is well-positioned for continued growth in 2026, driven by strategic initiatives and robust commercial execution.

CPRX — Catalyst Pharmaceuticals, Inc.